PT  - JOURNAL ARTICLE
AU  - Smit, J.M.
AU  - Van Der Zee, P.A.
AU  - Stoof, S.C.M.
AU  - Van Genderen, M.E.
AU  - Snijders, D.
AU  - Boersma, W. G.
AU  - Confalonieri, P.
AU  - Salton, F.
AU  - Confalonieri, M.
AU  - Shih, M-C.
AU  - Meduri, G.U.
AU  - Dequin, P.-F.
AU  - Le Gouge, A.
AU  - Lloyd, M.
AU  - Karunajeewa, H.
AU  - Bartminski, G.
AU  - Fernández-Serrano, S.
AU  - Suárez-Cuartín, G.
AU  - van Klaveren, D.
AU  - Briel, M.
AU  - Schoenenberger, C.M.
AU  - Steyerberg, E.W.
AU  - Gommers, D.A.M.P.J.
AU  - Bax, H.I.
AU  - Bos, W J. W.
AU  - Van De Garde, E.M.W.
AU  - Wittermans, E.
AU  - Grutters, J.C.
AU  - Blum, C.A.
AU  - Christ-Crain, M.
AU  - Torres, A.
AU  - Motos, A.
AU  - Reinders, M.J.T.
AU  - Van Bommel, J.
AU  - Krijthe, J.H.
AU  - Endeman, H.
TI  - Predicting individualized treatment effects of corticosteroids in community-acquired-pneumonia: a data-driven analysis of randomized controlled trials
AID  - 10.1101/2023.10.03.23296132
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.03.23296132
4099  - http://medrxiv.org/content/early/2023/10/03/2023.10.03.23296132.short
4100  - http://medrxiv.org/content/early/2023/10/03/2023.10.03.23296132.full
AB  - Background Corticosteroids could improve outcomes in patients with community-acquired pneumonia (CAP). However, we hypothesize that corticosteroid effectiveness varies among individual patients, resulting in inconsistent outcomes and unclear clinical indication. Therefore, we developed and validated a predictive, causal model based on baseline characteristics to predict individualized treatment effects (ITEs) of corticosteroids on mortality in patients with CAP.Methods We obtained individual patient data from six randomized controlled trials comparing corticosteroid therapy to placebo in 1,869 adult CAP patients. The study endpoint was 30-day mortality. We performed effect modelling through logistic regression and evaluated the predicted ITEs in terms of discrimination and calibration for benefit. Our modelling procedure involved variable selection, missing value imputation, data normalization, encoding treatment variables, creating interaction terms, optimizing penalization strength, and training logistic regression models. We evaluated discriminative performance using the newly proposed ‘AUC-benefit’.Findings The model identified high levels of CRP and glucose, at baseline, as main predictors for benefit of corticosteroid treatment. Using a decision threshold of ITE=0, the model predicted harm in 1,004 patient and benefit in 864 patients. We observed benefit in patients where the model predicted benefit, with an odds ratio of 0.5 (95% CI: 0.3 to 0.9) and a mortality reduction of 3.2% (95% CI: 0.7 to 5.6), and no statistically significant benefit in the patients where the model predicted harm, with an odds ratio of 1.1 (95% CI: 0.7 to 1.8) and a negative mortality reduction (hence, increase) of −0.3% (95% CI: −2.6 to 1.8). The model yielded an AUC-benefit of 184.9 (28.6 to 347.6, 95% CI), underestimated ITEs in the lower ITE region and slightly overestimated ITEs in the higher ITE region.Interpretation Our model has potential to identify patients with CAP who benefit from corticosteroid treatment, and aid in the design of personalized clinical trials. We will prospectively validate the model in two recent CAP trials.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our meta-analysis included individual patient data from six randomized controlled trials. Protocols of these six trials were approved by theinstitutional Medical Ethics Committees of the following institutions: - (Confalonieri et al.) Azienda Ospedaliero-Universitaria di Trieste, Strada di Fiume 447, 34100 Trieste, Italy. - (Snijders et al.) Medical Centre Alkmaar, Wilhelminalaan 15, 1812 JD Alkmaar, The Netherlands. - (Meijvis et al. and Wittermans et al.) St Antonius Hospital, Koekoekslaan 1, PO Box 2500, 3430 EM Nieuwegein, Netherlands - (Blum et al.) University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland - (Torres et al.) Servei de Pneumologia, Hospital Clinic, C/ Villarroel 170, 08036 Barcelona, SpainI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe proposed model (and corresponding dependencies), as well as the supplementary material, are available online on Github: https://github.com/jimmsmit/HTE_CAP. Individual participant data that underlie the results reported in this article are not publicly available. Requests should be directed to the corresonding authors of the included trials; data requestors will need to sign a data access agreement.https://github.com/jimmsmit/HTE_CAP/tree/main